| symbol |
UMRx |
|---|
| 会社名 | Unum Therapeutics Inc （ユナム・セラピュ―ティクス） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology called antibody-coupled T cell receptor (ACTR) is a universal engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087 ACTR087 (SEA-BCMA) and ACTR707. ユナム・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、がん治療のための免疫療法製品の開発・商業化に従事する。同社の抗体結合T細胞レセプタ―(ACTR)という独自技術は、各種の腫瘍タイプを標的にし、腫瘍特異的抗体と組み合わせて使用する細胞療法である。前臨床や臨床開発で承認され市販される抗体からも構成される。本社はマサチュ―セッツ州ケンブリッジ。 Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
|
|---|
| 本社所在地 | 200 Cambridge Park Drive Suite 3100 Cambridge MA 02140 USA |
|---|
| 代表者氏名 | Charles Wilson チャールズ・ウィルソン |
|---|
| 代表者役職名 | Founder President Chief Executive Officer and Director |
|---|
| 電話番号 | +1 617-945-5576 |
|---|
| 設立年月日 | 41699 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2018年 |
|---|
| 従業員数 | 53人 |
|---|
| url | www.unumrx.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/umrx |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -29.22900 |
|---|
| 終値（lastsale） | 9.86 |
|---|
| 時価総額（marketcap） | 294491065.28 |
|---|
| 時価総額 | 時価総額（百万ドル） 283.14150 |
|---|
| 売上高 | 売上高（百万ドル） 8.34000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 188.69450 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -29.49600 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Unum Therapeutics Inc revenues decreased 1% to $3.9M. Net loss applicable to common stockholders increased 33% to $15.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing va increase of 20% to $16.3M (expense). |
|---|
UMRX - ユナム・セラピュ―ティクス （Unum Therapeutics Inc.） ユナム・セラピュ―ティクス